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Extracellular Vesicles from Hypoxic Adipocytes and Obese
Subjects Reduce Insulin-Stimulated Glucose Uptake
Justyna Mleczko, Francisco J. Ortega, Juan Manuel Falcon-Perez, Martin Wabitsch,
Jose Manuel Fernandez-Real, and Silvia Mora*
Scope: We investigate the effects of extracellular vesicles (EVs) obtained from
in vitro adipocyte cell models and from obese subjects on glucose transport
and insulin responsiveness.
Methods and results: EVs are isolated from the culture supernatant of
adipocytes cultured under normoxia, hypoxia (1% oxygen), or exposed to
macrophage conditioned media (15% v/v). EVs are isolated from the plasma
of lean individuals and subjects with obesity. Cultured adipocytes are
incubated with EVs and activation of insulin signalling cascades and
insulin-stimulated glucose transport are measured. EVs released from hypoxic
adipocytes impair insulin-stimulated 2-deoxyglucose uptake and reduce
insulin mediated phosphorylation of AKT. Insulin-mediated phosphorylation
of extracellular regulated kinases (ERK1/2) is not affected. EVs from
individuals with obesity decrease insulin stimulated 2-deoxyglucose uptake in
adipocytes (p = 0.0159).
Conclusion: EVs released by stressed adipocytes impair insulin action in
neighboring adipocytes.
1. Introduction
White adipose tissue (WAT) regulates glucose and lipid home-
ostasis and functions as an endocrine tissue releasing adipokines
that contribute to regulate insulin sensitivity. White adipocytes
respond to insulin by activating glucose transport through the
translocation and activation of the glucose transporter GLUT4.[1]
Excess glucose is converted to glycerol for esterification of
fatty acids into triglycerides, which are later hydrolyzed to pro-
vide fatty acids during fasting. In obesity adipose cells fail to
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respond to insulin and glucose transport
and lipid regulation are impaired. During
WAT expansion, cells are exposed to lo-
cal hypoxia which contributes to the dys-
regulation of production and secretion of
adipokines.[2] Adipocytes are also exposed
to pro-inflammatory cytokines following
the recruitment, infiltration, and activa-
tion of macrophages within WAT, which
in turn further impair insulin action.
In recent years the importance of
a novel mechanism for intercellular
communication has emerged based
on the release of extracellular vesicles
(EVs).[3] EVs of various sizes, namely
exosomes (with sizes between 30–
150 nm), microvesicles (ranging from
100–1000 nm) or apoptotic bodies
(ranging 150–5000 nm) are released by
eukaryotic cells. EVs contain protein and
RNA species that regulate physiological
functions and gene expression in target cells[4] eliciting both au-
tocrine and paracrine effect in various cell types. EV composi-
tion and release aremodified in pathological conditions, with EVs
serving as biomarkers for human disease.[5,6]
Adipocytes have been shown to produce EVs of heterogeneous
sizes[7–10] which contribute to regulate lipid deposition[11,12] and
angiogenesis,[13] reviewed in.[14] Deng et al.[15] were the first to
report that EVs from adipose tissue explants from obese (ob/ob)
mice induced insulin resistance in vivo when injected into wild
typemice.[15] Despite the available data obtained in animal and in
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vitro studies, adipocyte-derived EVs remain poorly characterized
and limited information is available on their effects in normal
and pathophysiological conditions.
This study aimed at determining the impact of adipose-
released EVs on insulin action. Specifically, we tested the hypoth-
esis that EVs released by stressed adipocytes and those found
circulating in human obesity impact on insulin-stimulated glu-
cose uptake.
2. Experimental Section
2.1. Materials Reagents and Antibodies
Tissue culture media and reagents were from Sigma–Aldrich
(UK). B-tubulin antibody was from Sigma–Aldrich, Phospho-
Ser473 AKT, total AKT, phospho44p42, and total ERK (p44/p42)
antibodies were from Cell Signalling. Anti-CD81 antibody was
from AD Serotec (UK), anti-TSG101 (Ab83), anti-MHCI (clone
1158Y) anti-beta actin (Ab6276), anti-catalase (Ab15834), and
anti-GAPDH (Ab9484) antibodies were from Abcam (UK). Anti-
VEGF (VG-1) antibody was from Santa Cruz Biotechnology.
2.2. Cell Culture
Human Simpson–Golabi–Behmel syndrome (SGBS) cells were
grown and differentiated as described.[16] 3T3-L1 cells were cul-
tured and differentiated as described.[17] Prior to the isolation of
EVs from the conditioned media, cells were washed in PBS and
cultured in DMEMwithout any serum supplementation for 24 h.
For the macrophage conditioned media treated group, DMEM
was supplemented with 15% v/v of media from Bone Marrow
Derived Macrophages cells. Isolation of Bone Marrow Derived
Macrophages cells was carried out as described.[18] This media
contained on average 195 ng mL of IL6 and 150 ng mL–1 of
TNFα quantified by ELISA. For the hypoxia experiments, 3T3-L1
adipocytes were incubated in normoxia (95% air, 5% CO2) or in-
side an hypoxic chamber (hypoxystation1%O2, 5%CO2, and 95%
N2) for 24 h. EV treatments were carried out in DMEM without
supplementation.
2.3. Subjects
Plasma was obtained from n = 8 lean and from n = 9 women
with obesity recruited to the Endocrinology Service of the Hospi-
tal Universitari Dr. Josep Trueta (Girona, Spain), and were used
for EVs isolation. Exclusion criteria were: abnormal blood counts
and liver, kidney, or thyroid dysfunction, evidence of chronic ill-
ness other than obesity, chronic use of medication, acute illness,
or signs of infection in the month preceding enrolment. The
study protocol was approved by the Ethics Committee and the
Committee for Clinical investigation (CEIC) of the Hospital Uni-
versitari Dr. Josep Trueta. All subjects gave their written informed
consent. Plasma samples kept at –80 °C until the isolation of
EVs. Fasting glucose levels weremeasured by the glucose oxidase
method with a Beckman Glucose Analyzer 2 (Brea, CA). Plasma
insulin was determined by ELISA using a commercial kit (Cat-
alog E6000-K, Millipore, USA) following the manufacturer’s in-
structions.
2.4. Isolation of EVs
Isolation of EVs was carried out as described.[19,20] Briefly, cells
were grown and differentiated as indicated above in media con-
taining exosome-depleted FBS. Collection of conditioned media
was done following a 24-h incubation period in DMEM at either
normoxic or hypoxic conditions or DMEM containingMCM.Me-
dia was centrifuged at 2000× g for 10 min and filtered (0.22 μm)
to remove dead cells and cellular debris. The supernatant was
centrifuged at 17 000 × g for 30 min. The supernatant was cen-
trifuged at 100 000× g at 4 °C for 75min. The pellet resuspended
in sterile PBS and centrifuged again at 100 000 × g at 4 °C for
75 min. The final pellet containing small EVs was resuspended
in PBS, aliquoted, and stored at –80 °C until use. The same pro-
cedure was used for the isolation of plasma EVs, with a minor
modification. The plasma was diluted 1:3 volume in PBS prior to
the initial centrifugation. EV size distribution and concentrations
were determined by nanoparticle tracking analysis (NTA) using
a Malvern Nanosight NS300 instrument. EV preparations were
aliquoted and stored at –80 °C.
2.5. Cryo-Electron Microscopy
EVs were directly adsorbed onto glow-discharged holey carbon
grids (QUANTIFOIL, Germany) and processed as described.[21]
Images were obtained in a JEM-2200FS/CR transmission cryo-
electron microscope (JEOL, Japan).
2.6. Insulin-Stimulated 2-Deoxyglucose Uptake
Cells were washed in Krebs Ringer Hepes buffer (pH 7.4) twice
and incubated in this buffer for 45 min. Insulin was added at
100 nm for 15 min (SGBS cells) or 30 min (3T3L1) prior to
the assay. 2-Deoxyglucose uptake media was added containing
2 μCi mL–1 of 3H-2-deoxyglucose and unlabeled substrate at
0.1 mm final concentration. Uptake was allowed to proceed for
10 min (3T3L1 cells) or 15 min (SGBS) and stopped with four
washes in ice cold PBS containing 50 mm glucose. Cells were
lysed in 0.1 n NaOH and a fraction of lysate counted in scintilla-
tion cocktail. An aliquot of lysate was used for protein determina-
tion. Measurements were normalized to cellular protein content.
2.7. Cellular lysates and Western blotting
Cellular lysates and Western blotting were carried out as previ-
ously described.[22]
2.8. Extraction of RNA and qPCR analysis
Extraction of RNA and qPCR analysis was carried out as
previously described.[22] Primer sequences used:Glut1: For-
ward (5′-3′):GCTGTGCTTATGGGCTTCTC; reverse(5′-3′):
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Figure 1. Characterization of EVs released by 3T3-L1 adipocytes. A) Cryo-electron microscopy from Control (untreated), hypoxic or cells exposed to
macrophagemedia (MCM). Scale bar: 100 nm. B)NTA of EVs fromnormoxic/ hypoxic cells and control/MCM-exposed 3T3L1 adipocytes. C) Immunoblot
of cellular lysates (L) or EVs from control, hypoxic, or MCM exposed cells. Equal amounts of lysate or EVs (1 μg) were separated by SDS-PAGE and
immunoblotted with specific antibodies as indicated.
CACATACATGGGCACAAAGC; and Actb: forward(5′-3′): CCT-
GTGCTGCTCACCGAGGC, reverse(5′-3′): GACCCCGTCTCTC-
CGGAGTCCATC was used as normalizing gene.
2.9. Statistical Analysis
T-test or analysis of variance as indicated in the figure leg-
ends, were carried out using GraphPad Prism6 with a confidence
interval of 95% and statistical significance was considered if
p < 0.05.
3. Results
3.1. EVs from Hypoxic Adipocytes Impair Insulin-Stimulated
Glucose Uptake and AKT Activation in Adipocytes
In obesity, adipose tissue expansion results in local tissue hy-
poxia and inflammation. These two mechanisms cause cellu-
lar stress and thus, could contribute to the generation of EVs
by adipose cells. To evaluate the role of the EVs released by
adipocytes under these conditions independently, we generated
two in vitro models using the well-established 3T3L1 mouse adi-
pose cell line (Supporting Information Figure S1). For this, cells
were either incubated under hypoxia (1% O2), normoxia (21%
O2, control cells), in DMEM media alone, or supplemented with
macrophage conditionedmedia (MCM, 15%v/v) enriched in pro-
inflammatory cytokines. Both conditions caused the adipocytes
to become insulin resistant as seen by a decrease in the activation
of AKT following insulin stimulation (Supporting Information
Figure S1).
We next isolated EVs released by the cells into the condi-
tioned media and examined EV preparations by cryoelectron mi-
croscopy (Figure 1A) and immunoblotting (Figure 1C) to con-
firm purity of the preparations. EV size and concentration was
assessed by NTA (Figure 1B). EV size distribution was consis-
tent among experimental groups and consistent with that of ex-
osomes (Figure 1B). EV preparations were enriched in CD81,
a marker of exosomes, and markedly devoid of a mitochon-
drial (prohibitin-1) and endoplasmic reticulum (GRP78)markers
(Figure 1C).
To determine the effects of EVs on insulin sensitivity, 3T3-L1
adipocyte cells were either left untreated or treated with equal
amounts of EVs isolated from either normoxic, hypoxic, or cells
exposed to MCM. Insulin-stimulated glucose uptake was mea-
sured after 24 h. In untreated control cells insulin increased
2-deoxyglucose uptake by threefold over basal (Figure 2A–C).
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Figure 2. EVs from hypoxic adipocytes inhibit insulin-stimulated glucose uptake. 2-Deoxyglucose uptake in 3T3L1 adipocytes that were either left un-
treated (none) or treated for 24 h with 10 μg of EVs from control or hypoxic adipocytes (A) or with EVs from either control or MCM-exposed adipocytes
(B). The graphs show mean + SEM of a representative experiment and n = 3–4 biological replicates. Data is representative of three independent ex-
periments.*indicates p < 0.05, One-way analysis of variance. C) Heat treatment of hypoxic EVs restores insulin stimulated glucose uptake. Adipocytes
were left untreated or treated for 24 h with EVs from control or hypoxic cells or EVs from hypoxic cells that were heated 40 °C for 30 min. Following the
treatment 2-deoxyglucose uptake was determined. The graph show mean + SEM, *indicates p < 0.05, One-way analysis of variance (Tukey’s test).
Cells treated with EVs from control adipocytes exhibited a similar
response to untreated cells. However, cells treated with EVs from
hypoxic adipocytes displayed a 25% decrease in the insulin-
stimulated response, with no changes in the basal glucose trans-
port (Figure 2A and C). Uptake in cells treated with EVs from
cells exposed to MCM was no different than that of untreated
cells or treated with EVs from control cells (Figure 2B). Cellu-
lar viability was not affected by the EVs treatment (not shown).
Heating the hypoxic EV preparations to 40 °C for 30 min prior to
the treatment of cells restored insulin-stimulated glucose uptake
(Figure 2C).
To explore the molecular mechanisms, we determined the
expression of GLUT4 the main glucose carrier involved in the
insulin-mediated glucose transport, insulin receptor, and activa-
tion of the proteins involved in insulin signaling. No differences
were observed in the expression of Glut4 or the insulin receptor
between cell groups (Figure 3A). We determined the activation
of the insulin signaling pathway by monitoring phosphorylation
of Ser473 in AKT and of Thr201/Tyr204 on extracellular regu-
lated kinases (ERK) p44/p42 in response to insulin following the
treatment with EVs. In a dose dependent manner, we detected
a small but significant decline in AKT S473 phosphorylation in
cells treated with EVs from hypoxic cells compared to untreated
or cells treated with EVs from control adipocytes (Figure 3B, C).
We did not detect any difference in the activation of the ERK pro-
teins in any of the experimental groups (Figure 3B, C). No dif-
ferences in the expression levels of AKT or ERK proteins were
seen.
3.2. EVs from the Plasma of Subjects with Obesity Impair
Insulin-Mediated 2-Deoxyglucose Uptake
To confirm the above data in the context of human obesity, we
next isolated EVs from plasma obtained from lean and obese
women (Supporting Information Table S1) using previously es-
tablished ultracentrifugation protocols.[19] EV samples were an-
alyzed by western blotting to confirm the presence of EV mark-
ers (CD81, MHCI) and the absence of other cellular membrane
markers (insulin receptor, GRP78) and were compared to EVs re-
leased by 3T3-L1 adipocytes (Figure 4A). Plasma EVs contained
exosomal markers such as CD81 and MHCI, but were devoid
of TSG101 compared to EVs released by 3T3-L1 adipocytes (Fig-
ure 4A). EV particle distribution was similar to the cell models
and consistent with that of exosomes, with a peak around 100–
150 nm. (Figure 4B)
To preserve any species compatibility that could affect the en-
trance of EVs into cells, we next examined the effect of these EVs
on insulin action in the SGBS human adipocyte cell line. Fol-
lowing differentiation of cells into adipocytes, cells were incu-
bated in DMEM for 24 h to remove hormones and subsequently
treated with EVs from either lean women or women with obesity
at equal concentration (2× 105 EV mL–1) as determined by NTA,
and we assayed 2-deoxyglucose uptake in response to insulin as
described previously.[16] Transport was normalized to cellular pro-
tein content. Insulin-stimulated glucose transport was decreased
in cells treated with EVs obtained from women with obesity
(Figure 4C).
4. Discussion
Numerous stimuli induce the production of EVs in distinct cel-
lular types. Here, we sought to investigate the hypothesis that
EVs released by stressed adipocytes and those circulating in obese
subjects could affect insulin action.
The size distribution of our EV preparations was consis-
tent with those found in other systems including the Otsuka
Long-Evans Tokushima Fatty rats[23] and adipose tissue derived
mesenchymal stem cells.[24]
Previous reports found that obesity leads to an increase in EV
release in rodent animal models.[15,25] However, we did not detect
any differences in the concentration of circulating EVs found in
subjects with obesity (not shown). However, in agreement with[26]
themodel of hypoxic 3T3-L1 adipocytes producedmore EVs com-
pared to normoxic cells, a phenomena seen in other hypoxic cell
types. Hu et al.[27] found hypoxia upregulated the expression of
FIP4 a regulatory protein of the small GTP binding protein rab11,
which is present in adipocytes and has been involved in exosomal
release.[28] Thus, expression of genes regulated by HIF1α and
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Figure 3. EVs from hypoxic adipocytes inhibit insulin signaling. A) Immunoblot of cellular lysates from adipocytes treated for 24 h with 10 μg mL–1 of
EVs from control, hypoxic, or MCM-exposed cells. Equal amounts of lysates were immunoblotted with antibodies as indicated. B) 3T3L1 adipocytes were
left untreated or treated with 5–10 μg mL–1 EVs for 24 h (C: control, H: Hypoxia), and stimulated with insulin (100 nm, 30 min). Lysates were obtained
and immunoblotted with the indicated antibodies. C) Quantification of AKT and ERK phosphorylation. Graphs showmean± SD EV of n= 4 experiments
for AKT and n = 2 experiments phospho-ERK, ***indicates p < 0.01. One-way analysis of variance.
Figure 4. A) EVs from plasma (EV blood), EVs from human adipocytes (EV adipo), and adipocyte cellular lysates were separated by SDS-PAGE and
immunoblotted with antibodies for EV markers as indicated. B) Size distribution of plasma EVs by NTA. C) Insulin-stimulated 2-deoxyglucose uptake in
SGBS cells treated with 2 × 105 EV mL–1 of EVs obtained from lean (n = 8) or obese subjects (n = 9). Data shows mean ± SD EV, each EV was tested
in triplicate in two independent experiments, p = 0.0153 (t-test).
increased rab11-mediated trafficking could facilitate EV release
in adipocytes, however more experiments are needed to confirm
this.
EVs from hypoxic adipocytes and also from subjects with obe-
sity impaired insulin-stimulated glucose uptake in vitro in cul-
tured adipocytes. Our findings agree with those by Kranendonk
et al.[29] who found adipose tissue-derived EVs caused insulin re-
sistance in hepatocytes inhibiting insulin mediated AKT phos-
phorylation, with concomitant decrease in the expression of glu-
coneogenic genes.
Proteomic profiling studies of EVs released by adipocyte
cell models have been documented[8] including that of hypoxic
3T3-L1 cells[26] and of animal models of obesity and diabetes[23]
but to date not much information is available for circulating
EVs in human obesity. Available literature from in vitro sys-
tems suggests that EVs from adipocytes contain protein and RNA
species involved in regulating lipid metabolism and adipokine
production.[8,9,11,26,30–32]
While the precise molecular mechanisms are at present un-
known, we provide evidence that EV action implicates at least in
part the AKT pathway. The effect of hypoxic EVs on glucose trans-
port was thermolabile, suggesting an enzymatic activity may be
responsible for this effect, We found that PTEN, a protein phos-
phatase that reduces phosphatidylinositol 3,4,5-triphosphate lev-
els was present in EVs from hypoxic 3T3L1 adipocytes (not
shown). Thus, it is plausible that PTEN exported in EVs may be
active in recipient cells. Further experiments are necessary to con-
firm this.
Finally, since adipocytes produce adipokines that modulate in-
sulin action, it is possible that EVs could affect insulin signal-
ing indirectly through an adipokine-mediated mechanism. This
remains to be explored.
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To sum up, our study provides evidence that EVs released
by hypoxic adipocytes and in human obesity negatively impact
on insulin-stimulated glucose uptake, in part by inhibiting AKT
phosphorylation. The precise molecular entities need to be fully
elucidated and warrant further investigation.
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